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A Message From the President of IDSOG-USA
The International Infectious Diseases Society for Obstetrics and Gynecology-USA
(IIDSOG-USA) held its Third Annual Meeting in New Orleans, May 9 and 10,
1998. During the meeting, there was a heated discussion about antepartum screen-
ing and treatment of infection to lower the incidence of preterm labor and delivery.
On May 14, 1998, based upon the discussion at the meeting, drafted the
following letter that was sent to the membership asking their response to this
position statement.
POSITION STATEMENTmPREVENTION OF PRETERM BIRTH
Prevention of preterm birth is an important goal of obstetrical care. The
reason is obvious. Biologic immaturity at birth disproportionally contributes to
infant morbidity and mortality as well as to the high costs of neonatal inten-
sive nursery care.
Our assessment of published research, performed around the world, shows
an association between genitourinary microbial abnormalities and prematu-
rity. These conditions can exist either in asymptomatic women or in women
with symptoms so mild they will not be brought to the attention of the health
care provider. To ensure detection of women with genitourinary microbial
abnormalities, a strategy of universal screening will have to be employed. This
is not a foreign concept for obstetricians. For example, most American obste-
tricians practice universal screening of carbohydrate metabolism as a part of
standard prenatal care. The weight of evidence more strongly supports infec-
tion screening than this endocrinologic endeavor.
We recognize and acknowledge that the associations between these mi-
crobial abnormalities and prematurity need further study. We support con-
trolled intervention trials without a placebo arm to determine the best thera-
peutic strategies for these women. However, should all women at risk for
prematurity be denied potentially helpful therapeutic intervention while we
wait for the results of these trials? We do not think so.
We support antepartum screening for the following abnormal microbial
conditions in pregnancy. These include bacterial vaginosis, asymptomatic
bacteriuria, as well as lower genital tract colonizations with Chlamydia tracho-
matis, Trichomonas vaginalis, or Neisseria gonorrhea. There are easy-to-use sen-
sitive screening techniques available to determine these abnormalities and
those patients who test positive should be offered safe and effective treat-
ment.
The benefit of such a policy of intervention will require continuing assess-
ment of both basic microbiologic and immunologic research as well as and
clinical outcome studies. We believe such research will provide obstetricians
and their patients new opportunities to further reduce the risks of infants
being born too soon. The time for action is now.
To date, the majority of the responses have been favorable, with just under one
quarter of the favorable responders suggesting changes in the text that improved
Position Statementthe quality of the English. Anyone familiar with my syntax can understand the
magnitude of these responses. As you might expect with such a strong position
statement, nearly one quarter of the membership did not favor the society taking
this stand. All were concerned about either the lack of or paucity of data on the
treatment of asymptomatic women and felt that further prospective studies are
needed with a placebo arm. I have great respect for the scientific focus of the
dissenters, but I don’t agree with their stand. To withhold treatment for a patient
with bacterial vaginosis requires a belief that this syndrome causes no problems for
the pregnant woman. How can we deny one study after another that shows a
relationship with BV and postpartum pelvic infection? Knowing this, how can
anyone deny treatment when there are simple means to detect BV within minutes
of every vaginal examination during pregnancy? I agree with the purists that a
controlled prospective double blind study would be a satisfying exercise, but what
about the use of historical data as the control database? know of no one advo-
cating a placebo arm for prophylactic antibiotic studies in cesarean section or colon
surgery at the present time.
This should be grist for the mill of future discussion. What do the readers think?
The fourth annual meeting of the IIDSOG-USA will be held in Philadelphia,
Pennsylvania on May 15 and 16, 1999, the weekend before the annual meeting of
the American College of Obstetricians-Gynecologists. The society is pleased to
announce that two distinguished speakers have accepted our invitation to join the
meeting. Dr. Gordon Douglas, the former Chairman of Internal Medicine at Cor-
nell University School of Medicine and now vice president of Merck Vaccines at
Merck, Sharpe, and Dohme, will speak on "Immunization practices for the ob-
stetrician-gynecologist, currently and in the future." In addition, Robert Good,
PhD, MD, DSc, FACP, Distinguished Research Professor and Head ofAllergy and
Immunology, the University of South Florida Medical School, will speak on "Les-
sons concerning infectious diseases from study of patients with primary immuno-
deficiency diseases." I expect this to be an exciting and stimulating meeting for
every attendee.
Sincerely,
William J. Ledger, MD
President, IIDSOG-USA
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